Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial- stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility. The facility is a ...